51 results about "Dihydrochalcone" patented technology

The invention is applicable to the technical field of biological medicines, provides application of a natural compound of a targeted colon cancer drug resistance related protein, and particularly relates to application in preparation of drugs for preventing or treating colon cancer. According to the invention, a natural small molecule compound neohesperidin dihydrochalcone targeting the colon cancer drug resistance related protein TAGLN is screened out, and a new scheme is provided for reversing colon cancer drug resistance, so that the situation that no drug is available to the target spot is solved. Secondly, the invention also provides a scheme for combined use of neohesperidin dihydrochalcone and oxaliplatin, the scheme can significantly enhance the killing effect of oxaliplatin on drug-resistant colon cancer, and a new choice is provided for clinical treatment of colon cancer.

The present disclosure generally relates to dihydrochalcone compounds and their use for enhancing the perception of alcohol (ethanol) in food, beverages, and other comestible compositions. In certain aspects, the disclosure provides the use of such dihydrochalcone compounds to enhance an alcoholic (ethanolic) flavor of a beverage, for example, a low-alcohol or zero-alcohol beverage. In certain other aspects, the disclosure provides low-alcohol or zero-alcohol beverages containing such dihydrochalcone compounds.

The application belongs to the technical field of biological medicine, and provides application of a natural compound targeting colon cancer drug resistance related protein, in particular, application in preparation of a drug for preventing or treating colon cancer; the application screens out a natural small-molecule compound hesperetin dihydrochalcone targeting colon cancer drug resistance related protein TAGLN, and provides a new scheme for reversing colon cancer drug resistance, so as to solve the situation that no drug is available for the target point. In addition, the application further provides a scheme in which hesperetin dihydrochalcone is combined with oxaliplatin, and the scheme can significantly enhance the killing effect of oxaliplatin on drug-resistant colon cancer, thereby providing a new choice for clinical treatment of colon cancer.

The present invention relates to a confectionery containing psicose. Specifically disclosed is a sugar-free confectionery composition which is a jelly confectionery wherein the confectionery comprises: from 1% to 50% by weight of psicose; and from 1% to 50% of a polyol incremental sweetener in combination with a high-potency sweetener wherein the polyol incremental sweetener is selected from the group consisting of sorbitol, maltitol, isomaltitol, mannitol, xylitol, erythritol, and lactitol, and the high-potency sweetener is selected from the group consisting of kiwifruit protein, aspartame, acesulfame K, saccharin sodium, glycyrrhizin, Alisan, cyclohexylsulfamate, stevioside, dihydrochalcone, stevioside, stevioside, glycosylated stevioside, and Momordica grosvenori, and wherein the confectionery composition has a moisture content of from 15% to 20%, and wherein the sweetener is selected from the group consisting of ketoside, aspartame, acesulfame K, saccharin sodium, glycyrrhizin, Alisan, cyclohexylsulfamate, stevioside, dihydrochalcone, stevioside, glycosylated stevioside, and Momordica grosvenori; a method of making the sugar-free confectionery composition is also disclosed. The present invention provides a low calorie, low laxative confection comprising psicose with acceptable texture, stability, clarity, flavor delivery, and shelf life.

This invention discloses the application of plant extracts in the preparation of drugs that inhibit canine parvovirus, belonging to the field of biomedical technology. The plant extract is at least one selected from phlorizin, neomethylhesperidin-dihydrochalcone, tribulus terrestris saponin, stevia glycoside, soy isoflavones, berberine hydrochloride, diosgenin, and silymarin. Through in-depth research on various plant extracts, this invention has found that phlorizin, neomethylhesperidin-dihydrochalcone, tribulus terrestris saponin, stevia glycoside, soy isoflavones, berberine hydrochloride, diosgenin, and silymarin all exhibit significant inhibitory effects on canine parvovirus, with soy isoflavones showing particularly outstanding effects. This research provides a novel natural drug option for the prevention and treatment of canine parvovirus. This invention not only expands the application scope of natural plant extracts in the veterinary medicine field but also provides important technical support for the development of novel, highly effective, safe, and side-effect-free drug formulations for the prevention and treatment of canine parvovirus.

A flavor composition is provided. The composition includes a dihydrochalcone selected from the group consisting of hesperetin dihydrochalcone, hesperetin dihydrochalcone 4"-beta-D-glucoside, and combinations thereof, and an aromatic ingredient selected from the group consisting of 4-hydroxy-2H-furan-5-one, ethyl furanone, maltol, furfural, 5-methylfurfural, vanillin, benzaldehyde, and combinations thereof.

The purpose of the present invention is to improve the quality of sweetness in a food or beverage containing a sweetener. According to the present invention, in a food or beverage containing a sweetener, the food or beverage contains dihydrochalcones and minerals, and the content of dihydrochalcones and minerals is adjusted to a prescribed range.

The present disclosure generally relates to certain fatty acid amide compounds, such as hydroxy-α-sanshools, hydroxy-β-sanshools, and hydroxy-γ-sanshools, and the use of such compounds to impart or enhance sweetness, as well as mask bitterness, enhance mouthfeel, or mask astringency. In certain embodiments, such compounds are used in combination with other sweeteners or sweetness enhancers, such as flavonoids or dihydrochalcones. In certain aspects, the disclosure provides ingestible compositions that include such fatty acid amides. In some related aspects, the ingestible compositions are, or are included within, various flavored products, such as food products, beverage products, pharmaceutical products, or oral care products.

The present disclosure provides a use of a compound of Formula (I), wherein: - one of A and B is H and the other is (II); - G is R2 and E is H, -CH2-E' or (III), or G and E' are both single carbon atoms, said carbon atoms being directly linked together by a single bond, G being substituted by (IV) and E' being substituted by R6; - Re is H or OR1; - Rf is H or OR8, wherein R8 is H or C1-C12 alkyl; - each of R1, R2, R3, and R4 is independently H or C1-C12 alkyl; and - each of R5, R6, and R10 is independently H, OH, C1-C12 alkyl, or C1-C12 alkoxy, or a salt, ester, or solvate thereof, for preventing or reducing Legionella growth. Also provided is a kit comprising the compound.

The present invention provides a chalcone reductase mutant and its application. The mutant is obtained by the following single mutations at position 120 or 121 of the amino acid sequence of wild-type chalcone reductase: H120G / R / I / N, W121R / C / N / P / L / Q / A / F / Y. The present invention screens for chalcone reductase mutants with significantly higher selective catalytic reduction activity than the wild type by the activity of selectively catalytically reducing the carbon-carbon double bond of chalcone for the above mutants. The method of using the chalcone reductase described in the present invention as a biocatalyst for selectively reducing the carbon-carbon double bond of chalcone to synthesize dihydrochalcone has the advantages of simple reaction steps, mild reaction conditions, high catalytic efficiency, easy enzyme preparation, good thermal stability, etc., and mutants with catalytic performance significantly superior to the wild type are discovered. The present invention is of great significance for the industrial application of chalcone reductase and improves the application ability of chalcone reductase in selectively reducing the carbon-carbon double bond of chalcone.

A flavor composition is provided. The composition includes a dihydrochalcone selected from the group consisting of hesperetin dihydrochalcone, hesperetin dihydrochalcone 4″-beta-D-glucoside, and combinations thereof, and an aroma ingredient selected from the group consisting of furonol, ethyl furanone, maltol, furfural, 5-methyl furfural, vanillin, benzaldehyde, and combinations thereof.

The application relates to the application of natural plant extracts in the field of oral health, and particularly discloses the application of an extract of Ilex hainanensis Merr in oral health care products. The Ilex hainanensis Merr dichloromethane extract is eluted by high-concentration ethanol through a macroporous resin, and is rich in dihydrochalcone active ingredients, has significant inhibitory activity on Porphyromonas gingivalis and Fusobacterium nucleatum, and has no inhibitory effect on Streptococcus mutans, can selectively inhibit periodontal pathogenic bacteria without destroying the oral microecological balance, and is suitable for preparing toothpaste, mouthwash, oral spray and other oral health care products.

A flavor composition is provided. The composition includes at least one triterpenoid compound selected from the group consisting of pterocaryoside B, pterocaryoside A, cyclocarioside K and combinations thereof; and at least one sweetness modifier selected from the group consisting of steviol glycosides, mogrosides, dihydrochalcones, sweet proteins and combinations thereof.

The invention discloses a leucaena leucocephala-sourced dihydrochalcone compound, a preparation method thereof and application of the dihydrochalcone compound as a tyrosinase inhibitor. According to the invention, the tyrosinase inhibitor dihydrochalcone compound (+ / -)-4, 4 '-Methoxy-3, 3', beta-trihydroxydihydroxychalcone is extracted and separated from the leucaena leucocephala plant, the structural formula of the compound is as shown in the formula (I), the plant material is rich in source and is a renewable tissue part, and not only is the economic benefit good, but also the environment-friendly effect is achieved. Pharmacological experiments show that the tyrosinase inhibitory activity of the compound (+ / -)-4, 4 '-Methoxy-3, 3', beta-trihydroxydihydroxycholone is stronger than that of kojic acid, and the compound (+ / -)-4, 4 '-Methoxy-3, 3', beta-trihydroxydihydroxycholone) is expected to be further developed into a new whitening cosmetic synergist, a drug for treating pigmentation dermatosis, an insect control agent or a food preservative and the like, and has a good prospect.

Provided herein is a method of increasing production of a dihydrodiphenylpropanoid derivative compound (e.g., dihydrostilbenoid or dihydrochalcone compound) in a recombinant host cell. The method comprising: reducing or eliminating expression of a gene encoding a double-bond reductase polypeptide or activity of the double-bond reductase polypeptide encoded thereby; expressing a recombinant gene encoding a double-bond reductase selected from the group consisting of a first polypeptide, second polypeptide, third polypeptide, and combinations thereof. The first polypeptide comprises an amino acid sequence having at least 90% identity to the amino acid sequence as set forth in SEQ ID NO: 3, the second polypeptide comprises an amino acid sequence having at least 90% identity to the amino acid sequence as set forth in SEQ ID NO: 5, and the third polypeptide comprises an amino acid sequence having at least 90% identity to the amino acid sequence as set forth in SEQ ID NO: 7.

A flavor composition is provided. The composition includes a dihydrochalcone selected from the group consisting of hesperetin dihydrochalcone, hesperetin dihydrochalcone 4″-beta-D-glucoside, and combinations thereof, and an aroma ingredient selected from the group consisting of furonol, ethyl furanone, maltol, furfural, 5-methyl furfural, vanillin, benzaldehyde, and combinations thereof.

The invention discloses application of a plant extract in preparation of a medicine for inhibiting canine parvovirus, and relates to the technical field of biological medicine. The plant extract is at least one of phloretin, neohesperidin-dihydrochalcone, tribulus terrestris saponin, rubusoside, soy isoflavone, berberine hydrochloride, dioscin and silymarin. In-depth study on various plant extracts shows that phloretin, neohesperidin-dihydrochalcone, tribulus terrestris saponin, rubusoside, soy isoflavone, berberine hydrochloride, dioscin and silymarin all show a remarkable canine parvovirus inhibition effect, and the effect of soy isoflavone is particularly outstanding. The research result provides a brand new natural medicine choice for preventing and treating canine parvovirus. The application range of natural plant extracts in the field of veterinary medicine is expanded, and important technical support is provided for developing novel, efficient and safe canine parvovirus prevention and treatment medicine preparations without side effects.

A perfume composition is provided. The present invention relates to a composition comprising rutin and a sweetness modifier selected from the group consisting of mogroside, dihydrochalcone, hesperidin 3-acetate, brazilin, thaumatin, and combinations thereof.

The invention discloses a dihydrochalcone glucoside compound with the following structural formula, which is separated from malus toringoides, a high-fat model is obtained by inducing HepG2 cells through oleic acid, and the dihydrochalcone glucoside compound is used for treating the high-fat model, so that the dihydrochalcone glucoside compound is obtained. Experimental results show that the dihydrochalcone glycoside compound can effectively down-regulate accumulation of TG in human hepatoma cells (HepG2) treated by oleic acid at low concentration and reduce the number of lipid droplets, the effect is better than that of a positive drug fenofibrate, and the results show that the dihydrochalcone glycoside compound has a lipid-lowering effect and can be used for treating liver cancer cells (HepG2). The invention provides a new way for developing high-efficiency and low-toxicity lipid-lowering products; # imgabs0 #

The invention belongs to the technical field of traditional Chinese medicine detection, and particularly relates to a method for detecting the content of effective components of pseudo-ginseng and dragon's blood capsules. The invention provides a method for detecting the content of effective components in a pseudo-ginseng and dragon's blood capsule, which comprises the following steps: a, preparing a test solution: weighing pseudo-ginseng and dragon's blood capsule powder, adding methanol, performing ultrasonic treatment, and filtering to obtain the test solution; b, preparation of a reference substance solution: precisely weighing a ginsenoside Re reference substance, and adding methanol to dissolve the ginsenoside Re reference substance; the preparation method comprises the following steps: precisely weighing a proper amount of reference substances such as resveratrol, 4, 4-dihydroxy-2, 6-dimethoxy dihydrochalcone, loureirin A, loureirin B, loureirin C and loureirin D, and adding methanol for dissolving, thereby obtaining the resveratrol, 4, 4-dihydroxy-2, 6-dimethoxy dihydrochalcone and loureirin A; c, preparation of a reference substance solution: weighing the panax notoginseng total saponin reference extract, and adding methanol to dissolve the panax notoginseng total saponin reference extract to obtain the reference substance solution; and d, measuring and calculating the content. The method disclosed by the invention is high in accuracy, good in linearity, high in precision, good in separation degree and relatively good in repeatability.

The present disclosure provides pharmaceutical compositions comprising a microorganism capable of expressing an enzyme that converts a stilbene glycoside (e.g., polydatin) or a dihydrochalcone glycoside (e.g., phloridzin) to a stilbene (e.g., resveratrol) or a dihydrochalcone (e.g., phloretin), and a stilbene glycoside or a dihydrochalcone glycoside, or a pharmaceutically acceptable salt thereof. The present disclosure also provides methods for treating a Clostridioid.es difficile infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of any of the pharmaceutical compositions described herein. Methods for treating a Clostridioides difficile infection in a subject in need thereof comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a stilbene glycoside, a dihydrochalcone glycoside, a stilbene, or a dihydrochalcone, or a pharmaceutically acceptable salt thereof, are also provided herein. The present disclosure further provides kits, food products, and nutraceuticals.

This invention discloses a dihydrochalcone-based oral spray and its preparation method, belonging to the field of oral pharmaceutical formulations. The spray uses 1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenyl-1-propanone and 2',6'-dihydroxy-3',4'-dimethoxydihydrochalcone, isolated and purified from *Sarcandra glabra*, as active ingredients. It is solubilized using a medium-chain triglyceride / polyoxyethylene hydrogenated castor oil / propylene glycol self-microemulsification delivery system, and hydroxypropyl methylcellulose is introduced to enhance mucosal adhesion. This spray can spontaneously form nanoemulsion droplets in oral saliva, selectively inhibiting *Porphyromonas gingivalis* and *Fusobacterium nucleatum*, and is suitable for adjunctive treatment of gingivitis and periodontitis.

The invention relates to the technical field of methyl hesperidin dihydrochalcone processing, in particular to a production device and a production process of methyl hesperidin dihydrochalcone, and the production device comprises a reduction tank and supporting legs for supporting the reduction tank; a discharge hole is formed in the bottom of the reduction tank; a rotating motor is arranged in the middle of the top of the top cover; the stirring assembly is used for uniformly dispersing the catalyst and the reactant; the turbulent flow assembly comprises a reciprocating stirring module and a driving module; a turbulent flow assembly composed of an adjusting fluted disc, a sliding groove, a sliding plate, a movable stirring rod and a self-rotating stirring blade is arranged, a staggered meshing structure of a first driving plate and a second driving plate is combined, and forward and reverse periodic transmission formed by linkage with multiple sets of gears in the rotating process is utilized; the continuous reciprocating expansion and contraction movement of the sliding plate and the movable stirring rods connected with the sliding plate is achieved, strong radial turbulent flow disturbance can be generated in the reduction tank, bubbles are continuously scattered, and full mixing of three-phase materials is promoted.

The application discloses a mouthfeel modifying essence, characterized by comprising the following components: 40-50 parts of drinking pure water; 40-60 parts of alcohol; 8-12 parts of rebaudioside; 0.1-1 part of neomethyl hesperetin dihydrochalcone; 0-1 part of sweet orange oil; 0-1 part of maltol; and 0-1 part of butyl-tetradecanolide. The application can improve the adverse flavor generated by the sweetener by reasonably utilizing the synergistic effect between the fragrance raw materials.

The application discloses a 3'-geranyl-4,2',4',6'-tetrahydroxy dihydrochalcone against gram-positive bacteria, and a chemical structural formula of the dihydrochalcone is shown as formula (I). The application further provides a preparation method and application of the dihydrochalcone derivative. The 3'-geranyl-4,2',4',6'-tetrahydroxy dihydrochalcone has significant antibacterial activity against gram-positive bacteria, MRSA retention bacteria activity, and can significantly inhibit the formation of gram-positive bacterial biofilm.

The invention relates to the technical field of medicines, and discloses an application of a dihydrochalcone compound in preparation of a medicine for resisting skin pigmentation or reducing uric acid, the structural formula of the dihydrochalcone compound is as shown in formula I. In the formula I, R1 is tert-butyl or hydrogen; r2 is ethyl, propyl, chlorine, fluorine, hydrogen or tertiary butyl; and R3 and R4 are respectively hydroxyl or benzyloxy. The compound has obvious in-vitro skin pigmentation disease resistance activity, has strong tyrosinase inhibition capability on B16F10 mouse melanoma cells, has good xanthine oxidase (XOD) inhibition activity, can obviously reduce uric acid in an HK-2 hyperuricemia cell model, and has good potential medicinal value.

The invention provides an engineering bacterium for producing dihydrochalcone compounds as well as a construction method and application of the engineering bacterium. The engineering bacterium comprises a chassis bacterium and a coding gene of flavone hydroxylase HpaBC transferred into the chassis bacterium for expression. A coding gene of methyltransferase OMT which is co-expressed in the chassis bacteria, a coding gene of co-expressed glycosyl transferase OGT and a coding gene of co-expressed rhamnosyl transferase 1, 2RhaT are also transferred into the engineering bacteria. By utilizing the engineering bacteria, not only can biosynthesis of dihydrochalcone compounds such as 3-hydroxy phloretin, hesperetin dihydrochalcone, hesperetin dihydrochalcone glucoside, neohesperidin dihydrochalcone and the like by heterologous in-vitro phloretin addition be realized, but also efficient biosynthesis of the dihydrochalcone compounds by taking a simple carbon source as a source can be realized, and the method has the advantages of high efficiency, high yield and high yield. And the yield of the 3-hydroxy phloretin, the yield of the hesperetin dihydrochalcone, the yield of the hesperetin dihydrochalcone glucoside and the yield of the neohesperidin dihydrochalcone can reach 204.11 mg / L, 127.29 mg / L, 183.2 mg / L and 98.36 mg / L respectively.

The present invention discloses an aromatic composition comprising: (a) hesperidin dihydrochalcone or a salt thereof; and (b) a high-fructose corn syrup (HFCS) that provides high sweetness but low calorie intake.

The invention discloses a dihydrochalcone compound Invoucrasin H as well as a preparation method and application of the dihydrochalcone compound Invoucrasin H. The Invoucrasin H is obtained by being separated from a leguminosae seguinea plant ephedra cochinchinensis. Researches on an in-vivo lipopolysaccharide-induced acute lung injury mouse model and an in-vitro human bronchial epithelial cell inflammation model show that the compound can significantly reduce the levels of inflammatory factors IL-6, IL-1beta and TNF-alpha, and alleviate lung tissue inflammatory response and pathological injury. The invention also provides an application of the Invoucrasin H in preparation of medicines for preventing and treating acute lung injury and related inflammatory lung diseases. The invention provides a new natural small molecule candidate drug for treating acute lung injury.

A flavor composition is provided. The composition includes advantame; and at least one taste modifier selected from the group consisting of i) a sweetness modifier comprising a dihydrochalcone, ii) a positive allosteric modulator of the human sweet taste receptor, and iii) combinations thereof.